References
1. Weda M, Hoebert J, Vervloet M, et al. Study on off-label use of
medicinal products in the European Union. European Union2017.
2. Commission E. State of Paediatric Medicines in the EU 10 years of the
EUPaediatric Regulation.
https://ec.europa.eu/health/system/files/2017-11/2017_childrensmedicines_report_en_0.pdf.
Published 2017. Accessed March 8, 2022.
3. conect4children. Collaborative Netwerk for European Clinical Trials
for Children.
www.conect4children.org.Accessed March 8, 2022.
4. Smits A, Annaert P, Cavallaro G, et al. Current knowledge, challenges
and innovations in developmental pharmacology: A combined
conect4children Expert Group and European Society for Developmental,
Perinatal and Paediatric Pharmacology White Paper. British journal
of clinical pharmacology. 2021.
5. Aurich B, Apele-Freimane D, Banaschewski T, et al. c4c: Paediatric
pharmacovigilance: Methodological considerations in research and
development of medicines for children - A c4c expert group white paper.British journal of clinical pharmacology. 2021.
6. Walsh J, Schaufelberger D, Iurian S, et al. Path towards efficient
paediatric formulation development based on partnering with clinical
pharmacologists and clinicians, a conect4children expert group white
paper. British journal of clinical pharmacology. 2021.
7. Moretti F, Ruiz F, Bonifazi F, Pizzo E, Kindblom JM. Health
technology assessment of paediatric medicines: European landscape,
challenges and opportunities inside the conect4children project.British journal of clinical pharmacology. 2021.